Affinity-based methods for using transferrin receptor-binding proteins
AssigneeDenali Therapeutics Inc.
InventorsMark S. Dennis, Jennifer Getz, Mihalis Kariolis, Adam P. Silverman, Robert C. Wells, Joy Yu Zuchero
Life of this patent
Estimating the term…
Abstract
Provided herein are methods for transporting agents across the blood brain barrier. In some embodiments, the agents bind to therapeutic targets for the treatment of neurodegenerative diseases. As described herein, the agents are linked to proteins that bind to a transferrin receptor.
Claims25
A method for transporting an agent that binds to a therapeutic target across the blood-brain barrier (BBB) of a mammal, comprising exposing the BBB to a protein that binds to a transferrin receptor (TfR) with an affinity of from about 400 nM to about 2 μM, wherein the protein is linked to the agent and transports the linked agent across the BBB.
A method for treating a neurodegenerative disease, comprising administering to a mammal a protein that binds to a TfR with an affinity of from about 400 nM to about 2 μM, wherein the protein is linked to an agent that binds to a therapeutic target implicated in the neurodegenerative disease, thereby prolonging exposure of the brain of the mammal to the agent.
Dependencies are inferred from the claim text.